C9orf72 and amyotrophic lateral sclerosis: Research groups are currently working with ISIS Pharmaceuticals to develop an antisense strategy for C9orf72-based ALS, working under the hypothesis that reducing mutant C9orf72 transcripts using AOs will ameliorate toxic aggregations of expanded repeat mRNA, which present as nuclear foci in brain and spinal cord in affected patients [191,204].